NIH Reporter #1R43HL178322-01A1

A cardiopulmonary unit-on-a-chip to investigate the pathophysiology and develop targeted treatments for right ventricular hypertrophy caused by pulmonary arterial hypertension

This award funds the development of a microfluidic cardiopulmonary unit-on-a-chip to model pulmonary arterial hypertension-induced right ventricular hypertrophy, enabling detailed study and targeted treatment development.

Description

Development of a microfluidic ‘cardiopulmonary unit-on-a-chip’ model to study PAH-induced right ventricular hypertrophy (RVH). The project aims to incorporate features such as rhythmic contraction, blood flow-induced pressure, and electrical stimulation, cultivate relevant cells to replicate PAH-RVH pathologies, explore effects of biological sex and sex hormones, and assess current PAH and RV-targeted medications. The innovation uses microengineering to understand pathological processes and develop therapies, with potential impact on personalized medicine and ethical research practices.

View original record